HOME >> MEDICINE >> NEWS
Antiretroviral therapy may prevent excess risk of some cancers in people with HIV

In people infected with human immunodeficiency virus (HIV), highly active antiretroviral therapy (HAART) may prevent most excess cases of Kaposi sarcoma and non-Hodgkin lymphoma, according to a new study in the March 16 issue of the Journal of the National Cancer Institute.

Studies of people with acquired immunodeficiency syndrome (AIDS) have reported increased risks of several cancers, including Kaposi sarcoma, non-Hodgkin lymphoma, and, to a lesser extent, anal cancer, invasive cervical cancer, and Hodgkin lymphoma. However, less well understood are the associations of these cancer risks with the use of HAART, with immune status, and with behavioral risk factors such as smoking.

To estimate excess cancer risk in people infected with HIV and investigate the modifying effects of the use of HAART and behavioral factors on this cancer risk, Gary M. Clifford, Ph.D., of the International Agency for Research on Cancer in Lyon, France, and colleagues analyzed data from the Swiss HIV Cohort Study and Swiss cancer registries on more than 7,300 people infected with HIV.

People with HIV in the study had a highly elevated risk of Kaposi sarcoma and non-Hodgkin lymphoma. They also had an increased risk of anal cancer, Hodgkin lymphoma, cervical cancer, liver cancer, cancer of the lip, mouth, and pharynx, and non-melanoma skin cancer. People who used HAART had lower risks of Kaposi sarcoma and non-Hodgkin lymphoma compared with those who did not use HAART, although even with HAART these tumors occurred 20 times more frequently than they do in the general population without HIV/AIDS. HAART use was not associated with lower risks of Hodgkin lymphoma or other cancers. Although people infected with HIV had increased risks of cancers of the lung, lip, mouth, and pharynx, no cases of these cancers were found among nonsmokers.

"In conclusion, HAART treatment may prevent excess risk of [Kaposi sarcoma] and non-Hodgkin lymphoma, but not that of Hodg
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
15-Mar-2005


Page: 1 2

Related medicine news :

1. Antiretrovirals reduce mother-to-child HIV-1 transmission when started after childbirth
2. Antiretroviral therapy after birth decreases mother-to-child HIV transmission
3. Antiretroviral therapy around childbirth reduces risk of mother-to-child HIV-1 transmission
4. New Clinical Data Indicates LEUKINE Maintains Viral Suppression And Extends Duration Of Antiretroviral Therapy Utility In People With AIDS
5. Declining National Rates Of HIV-Related Deaths And Illnesses Due To Combination Antiretroviral Therapy With Protease Inhibitors
6. Study shows patch therapy may be as effective as oral medications
7. Novel therapy tested in mice could chase away cat allergies
8. Drug therapy may be comparable to invasive cardiac procedures for elderly patients with heart attack
9. Risk of cardiac death after radiotherapy for breast cancer has declined, study finds
10. Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer
11. Breakthrough in medical research: New chemotherapy gives hope to brain tumour patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... practice partnerships through affiliations and de novo development, today announced Cumberland Skin ... , Cumberland Skin Surgery and Dermatology, with offices in both Hermitage and Lebanon, ...
(Date:8/16/2017)... ... August 16, 2017 , ... The ... a three-year grant totaling $975,000, renewing its funding from the Health Resources and ... , This funding marks, the fourth time the HRSA administration has renewed its ...
(Date:8/16/2017)... ... , ... A global leader in the treatment of clubfoot, CURE International ... states—bringing the country one step closer to eliminating clubfoot as a lifelong disability by ... track to enroll 10,000 children in the clubfoot treatment program in this year alone. ...
(Date:8/16/2017)... ... August 16, 2017 , ... Melbourne’s reign as the world’s ... Economist Intelligence Unit’s (EIU) annual Liveability Index. , The Index surveys 140 of the ... began in 2006, Melbourne has consistently come in the top three of the index. ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... $5.99, eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery ... of God's love, and all the many ways God shows love to those ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: ... second-quarter 2017 and updated financial guidance for the full-year ... Highlights Reported net sales of $397.6 ... quarter. Net sales at constant currency (organic) grew by ... $0.51, compared to $0.60 in the prior-year quarter. Second-quarter ...
(Date:7/26/2017)... Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced ... Altemia TM , an oral therapy for pediatric patients ... (SCD). The SCOT Trial, is a double-blind, placebo-controlled, dose-finding, ... Altemia TM in pediatric patients aged 5-17 years ... "The completion of ...
(Date:7/25/2017)... LAUDERDALE, Fla. , July 25, 2017  Debbie,s Dream Foundation: Curing Stomach ... Luncheon on Monday, September 25, 2017 at the Bonaventure Resort & Spa in ... ... Gendler, DDF Founder and President Debbie Zelman, and Luncheon Committee Co-chair Sabrina Kurzman. ... ...
Breaking Medicine Technology:
Cached News: